The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2021 | Classification of high-risk mutations in MDS
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel, outlines the key points from his talk on low-risk disease with high-risk mutation in myelodysplastic syndromes (MDS). Prof. Mittelman explains the parameters used by classifications like the International Prognostic Scoring System (IPSS-R) such as the percentage of blasts in the bone marrow and cytogenetics. Currently, genetic profiles are not used in such prognostic classifications despite extensive research on mutations associated with favorable as well as poor prognosis. However, Prof. Mittelman talks of an international effort to develop prognostic models which incorporate such genetic and cytogenetic information, which may improve diagnosis and prognosis and also aid the administration of personalized treatment. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
